Compare Old Dominion Freight Line Inc (ODFL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Old Dominion Freight Line Inc vs Viatris Inc — how do they compare? Old Dominion Freight Line Inc trades at $183.23 (market cap $36.42B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Old Dominion Freight Line Inc is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.74%). Which is the better fit depends on your goals — on Pluang, investors hold Old Dominion Freight Line Inc for 76 Days and Viatris Inc for 57 Days on average.
| ODFL | VTRS | |
|---|---|---|
Market Cap | $36.42B | $20.12B |
Volume | 1,668,932 | 7,543,511 |
Sector | Industrials | Health |
52-Week High | $248.73 | $18.27 |
52-Week Low | $126.29 | $9.74 |
Typical Hold Time | 76 Days | 57 Days |
Enterprise Value | $36.15B | $32.24B |
Dividend Yield | 0.66% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Old Dominion Freight Line (ODFL) trades at $181.65, up 2.04% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 19.44% net margins and 24.82% ROE, though revenue declined to $5.5B in 2025. Recent news highlights a 4.9% general rate increase effective October 5, 2026, aimed at offsetting operating costs while supporting service investments.
ODFL presents a mixed outlook with Wall Street's $230.93 consensus target suggesting 27% upside, yet technical indicators remain bearish. The stock's premium valuation (P/E 33.77) requires sustained earnings growth, while competitive pressures and freight demand volatility pose risks. Institutional buying and oversold technical conditions may support near-term recovery potential.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue trends show a slight decline from $16.3B in 2022 to $14.3B in 2025, but net losses have widened significantly, reaching -$3.51B in 2025. Positive cash flow generation and a dividend payment scheduled for September 2026 highlight financial stability amid profitability challenges.
The outlook for VTRS is mixed; analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside, supported by strong cash flow and recent product approvals. However, persistent net losses, high P/E ratio of 236.2, and substantial long-term debt of $14.04B pose risks. Investors should weigh the potential for operational turnaround against ongoing profitability concerns and competitive pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
